Ajit Singh Takes the Helm at Harbinger Health and Flagship Pioneering

Major Leadership Change at Harbinger Health

In a notable transition, Ajit Singh, Ph.D., has been appointed as the CEO of Harbinger Health and CEO-Partner of Flagship Pioneering, effective August 11, 2025. Flagship Pioneering, a leader in bioplatform innovation, and Harbinger Health, which specializes in the early detection of cancer, announced this significant appointment, highlighting Singh's extensive experience in advanced diagnostics.

Prior to this role, Dr. Singh was a board member at Harbinger since 2024. He succeeds Stephen Hahn, M.D., who will take on the role of CEO Emeritus and Special Advisor while remaining on the Board of Directors. This transition marks a pivotal moment for the company, which is focused on developing innovative products that can transform early cancer detection.

Dr. Singh brings a robust background in the diagnostics field, deriving insights from his past roles at Siemens and other diagnostics-focused companies that have successfully launched critical in vitro diagnostics products, particularly in oncology. His arrival comes as Harbinger aims to expand its capabilities and enhance its presence in cancer detection technology, a crucial need in the healthcare sector.

In a statement, Doug Cole, M.D., Co-founder and Board Chair of Harbinger, expressed gratitude for Dr. Hahn's foundational leadership at Harbinger, acknowledging his pivotal role in establishing a validated platform and creating partnerships with leading cancer research institutions. He emphasized that the company will continue to benefit from Dr. Hahn's guidance in his new capacity.

Dr. Singh's deep understanding of the diagnostics industry and proven track record in leading growth-oriented companies are expected to be instrumental in advancing Harbinger’s objectives. He noted the vital need for early cancer detection solutions and expressed enthusiasm for driving the company’s mission forward, leveraging cutting-edge insights and technologies, including AI, to improve patient outcomes significantly.

Harbinger Health is at the forefront of revolutionizing early cancer detection through its advanced blood-based tests, which aim to identify cancer by detecting specific methylation patterns in cell-free circulating tumor DNA (ctDNA) well before symptoms manifest. The company utilizes proprietary insights regarding cancer biology combined with innovative analytical methodologies and AI to create new diagnostic and screening products.

Recently, Harbinger presented promising data showcasing the potential effectiveness of its assays in identifying high-incidence, high-mortality cancers linked to obesity and advancements designed to improve the performance of cancer detection signals.

About Ajit Singh

Ajit Singh's impressive background includes investments in early-stage technology and life sciences at Artiman Ventures, and previously, he was President and CEO of BioImagene, a digital pathology company that was acquired by Roche. His career includes nearly two decades at Siemens, where he held various leadership roles, ultimately serving as CEO of Digital Radiology and Medical Informatics, focusing on advanced diagnostic technologies. He also holds a Ph.D. in Computer Science from Columbia University and has authored several publications and patents in his field.

About Harbinger Health

Founded through extensive research by Flagship Pioneering, Harbinger Health is committed to transforming cancer detection by developing new screening and diagnostic approaches. The company envisions a future marked by proactive cancer care that emphasizes prevention rather than reactive solutions, pivoting towards a model where cancer identification is routine, fostering a change that could significantly impact healthcare systems globally.

For more information on Harbinger and its innovative cancer detection initiatives, visit Harbinger Health.